Navigating the official data regarding a 5-amino-1mq human clinical trial requires distinguishing between early-stage preclinical literature and registered human trials on ClinicalTrials.gov. As a selective nicotinamide N-methyltransferase (NNMT) inhibitor, 5-amino-1-methylquinolinium (5-amino-1MQ) is widely investigated in vitro and in animal models for its potential to elevate intracellular NAD+ levels and optimize mitochondrial bioenergetics. PX1 Research provides high-purity, analytical-grade 5-amino-1MQ exclusively for laboratory experimentation and preclinical research use.
Navigating the official data regarding a 5-amino-1mq human clinical trial requires distinguishing between early-stage preclinical literature and registered human trials on ClinicalTrials.gov. As a selective nicotinamide N-methyltransferase (NNMT) inhibitor, 5-amino-1-methylquinolinium (5-amino-1MQ) is widely investigated in vitro and in animal models for its potential to elevate intracellular NAD+ levels and optimize mitochondrial bioenergetics. PX1 Research provides high-purity, analytical-grade 5-amino-1MQ exclusively for laboratory experimentation and preclinical research use.
A formal 5-amino-1mq human clinical trial registered under ClinicalTrials.gov does not currently exist as a completed, peer-reviewed Phase II or Phase III efficacy study. While researchers frequently search terms such as 5-amino-1mq clinicaltrials.gov or clinicaltrials.gov 5-amino-1mq to locate human safety datasets, current published literature remains localized to preclinical rodent models, primary cell cultures, and enzymatic assays. Investigational queries surrounding a 5-amino-1mq clinical trial human framework typically stem from translational interest in targeting adipose tissue metabolism via enzyme inhibition.
The absence of extensive phase-tier entries under a 5-amino-1-methylquinolinium clinical trial query on public registries underscores the experimental status of the small molecule. In laboratory settings, 5-amino-1MQ is categorized strictly as a targeted enzyme inhibitor rather than an approved therapeutic. Principal investigators referencing 5-amino-1MQ research protocols rely on foundational data from university-led rodent trials, which established the compound's selective inhibition profile without compromising surrounding methyltransferase activity.
Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme responsible for catalyzing the methylation of nicotinamide (NAM) using S-adenosylmethionine (SAM) as a methyl donor, yielding 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). In metabolic research, high NNMT expression correlates with reduced intracellular NAD+ availability and suppressed mitochondrial respiration. By introducing 5-amino-1MQ reagent into cellular assays, researchers inhibit NNMT, preventing the degradation of NAM and allowing the NAD+ salvage pathway to recycle NAM back into NAD+.
Preclinical studies indicate that elevated NAD+ pools enhance sirtuin-1 (SIRT1) activity and downstream peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) signaling. This cascade stimulates mitochondrial biogenesis, increases basal metabolic rate, and promotes fatty acid oxidation in adipocyte models. In vitro assays demonstrate that 5-amino-1MQ exhibits a low micromolar inhibitory concentration (IC50 ~ 1.2 µM), exhibiting high specificity for NNMT without significantly inhibiting structurally similar methyltransferases such as HNMT, COMT, or TPMT.
To date, searching for a "5-amino-1-methylquinolinium" clinical trial humans dataset yields zero FDA-approved, double-blind human clinical trials. The scientific literature relies heavily on rodent experiments, notably high-fat diet-induced obesity (DIO) mouse models. In these animal studies, parenteral administration of 5-amino-1MQ resulted in marked reductions in adipocyte volume, decreased total body weight, and reduced plasma cholesterol levels without altering caloric intake.
Because translational research has not progressed to large-scale human trials, preclinical investigators utilize isolated mammalian tissue samples and primary human adipocyte cultures to simulate metabolic flux. Laboratory data derived from these in vitro assays validate that NNMT inhibition directly shifts cellular bioenergetics away from lipid storage and toward oxidative phosphorylation. Detailed documentation of these cellular kinetics is indexed in the broader PX1 Research Library.
When reviewing "5-amino-1mq" human clinical trial safety literature, researchers must analyze potential off-target effects related to global methyl-donor kinetics. Because NNMT consumes SAM, high NNMT activity depletes the cellular methyl pool. Inhibiting NNMT restores SAM levels, which supports general DNA, RNA, and protein methylation pathways. However, complete system-wide NNMT knockout or high-dose chronic inhibition requires careful monitoring in animal models to rule out alterations in hepatic gene expression or localized methyl imbalances.
In vivo rodent evaluations have demonstrated favorable short-term safety profiles, showing no overt neurotoxicity, hepatotoxicity, or behavioral alterations at standard laboratory dosages. Nevertheless, because comprehensive toxicokinetic profiling in humans remains unperformed, researchers evaluating 5-amino-1MQ must handle the compound under controlled in vitro and animal laboratory standards. Reagent safety parameters, hazardous substance handling, and analytical purity profiles must be reviewed via chemical safety data sheets (MSDS) prior to assay setup.
In metabolic research, 5-amino-1MQ occupies a distinct mechanistic niche compared to peptide-based metabolic regulators. While peptide compounds primarily interact with cell-surface G-protein coupled receptors (GPCRs), 5-amino-1MQ acts intracellularly as a direct competitive enzyme inhibitor.
For example, mitochondrial-derived peptides such as MOTS-c peptide act on AMP-activated protein kinase (AMPK) pathways to regulate insulin sensitivity, whereas lipolytic fragment peptides like AOD-9604 compound stimulate beta-3 adrenergic pathways to trigger lipolysis. In contrast, 5-amino-1MQ directly preserves the intracellular coenzyme pool by inhibiting NNMT. Researchers interested in broader metabolic cascade studies often evaluate these agents in parallel assays to compare cell-signaling responses. Further comparative details are available through our wholesale research portal.
Given the precise enzymatic assays required for NNMT inhibition studies, compound purity is paramount. Impurities in small-molecule synthesis can alter binding kinetics, induce baseline cytotoxicity, or produce false-positive results in fluorometric enzymatic assays. PX1 Research enforces strict quality control parameters for all laboratory compounds, guaranteeing reproducible results across experimental replicates.
Every batch of 5-amino-1MQ undergoes rigorous analytical testing in ISO 17025 accredited, third-party laboratories. Evaluation protocols include reverse-phase high-performance liquid chromatography (RP-HPLC) to confirm chemical purity exceeding 99% and electrospray ionization mass spectrometry (ESI-MS) to confirm exact molecular weight. Furthermore, baseline endotoxin testing ensures that reagent preparations are suitable for sensitive cellular culture systems. Complete batch-specific Certificates of Analysis (COAs) are accessible through our research peptide directory.
5-Amino-1MQ (5-amino-1-methylquinolinium iodide or salt form) is supplied as a crystalline solid powder intended strictly for laboratory reconstitution. Due to its chemical structure, the compound exhibits distinct solubility profiles compared to standard hydrophilic peptides. It displays optimal solubility in dimethyl sulfoxide (DMSO) and dimethylformamide (DMF), with limited solubility in aqueous buffers without co-solvents.
For in vitro enzymatic assays, stock solutions should be prepared in anhydrous DMSO at concentration ranges appropriate for microplate titration. Stock aliquots must be sealed under inert gas (nitrogen or argon) to prevent hygroscopic degradation and stored at -20°C or -80°C. Freeze-thaw cycles should be minimized to preserve structural integrity. All solution preparation should occur within a calibrated laminar flow hood using sterile, pyrogen-free laboratory consumables.
The gap between preclinical success and formal 5-amino-1-methylquinolinium clinical trial completion highlights common challenges in translational pharmacology. Small-molecule development requires extensive pharmacokinetics (PK), pharmacodynamics (PD), absorption, distribution, metabolism, and excretion (ADME) optimization before Phase I human safety trials are authorized.
Currently, academic and industrial laboratories use 5-amino-1MQ to map the basic biology of NNMT in metabolic syndrome, sarcopenia, and oncology models. Because NNMT is overexpressed in certain cancer cell lines and diseased adipose tissues, 5-amino-1MQ serves as an essential benchmark molecule for developing next-generation selective inhibitors. Researchers looking to explore these pathways can reference ongoing updates in our analytical research hub.
PX1 Research serves as a premier USA-based supplier of high-purity research compounds for academic institutions, biotechnology organizations, and independent analytical laboratories. All synthetic small molecules and research peptides are manufactured in US-based, GMP-compliant facilities under strict quality management systems.
To protect sample integrity during transport, orders are packed in climate-controlled, protective packaging and dispatched via same-day shipping (Monday through Friday) from our dual distribution hubs in California and Arizona. Each shipment includes lot-traceable documentation referencing full HPLC and MS analytical data, assuring investigators that their materials meet exact research specifications.
What is the status of a 5-amino-1mq human clinical trial on ClinicalTrials.gov?
Currently, there are no completed or active Phase II/III 5-amino-1mq human clinical trials registered on ClinicalTrials.gov. The compound remains in the preclinical phase, with research limited to cell cultures, tissue assays, and animal models.
Are there published datasets for a "5-amino-1-methylquinolinium" clinical trial humans study?
No, published peer-reviewed human clinical trials for 5-amino-1-methylquinolinium do not exist. Primary scientific literature focuses exclusively on rodent models of obesity, cellular metabolic flux assays, and isolated enzyme kinetics.
What does literature say about "5-amino-1mq" human clinical trial safety?
Because human clinical trials have not been conducted, formal human safety data is unavailable. Preclinical rodent studies report selective NNMT inhibition without overt systemic toxicity at experimental doses, but the compound is restricted strictly to laboratory research.
Why do researchers search for "5-amino-1mq clinicaltrials.gov" or "clinicaltrials.gov 5-amino-1mq"?
Investigators search these queries to determine if translational research has advanced from animal models to human testing. Searching ClinicalTrials.gov allows researchers to verify whether regulatory bodies have approved human safety or efficacy protocols for the compound.
How does a 5-amino-1mq clinical trial human protocol differ from rodent research models?
A human clinical trial protocol requires extensive Phase I safety, tolerability, and pharmacokinetic profiling. In contrast, rodent models focus on high-dose efficacy outcomes, such as changes in adipocyte size, metabolic rate, and intracellular NAD+ concentrations under high-fat diet conditions.
What is the primary target evaluated in a 5-amino-1-methylquinolinium clinical trial investigation?
The primary molecular target is Nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme involved in cellular energy regulation, methyl-donor balance, and NAD+ degradation.
What solvent is recommended for reconstituting 5-amino-1MQ in laboratory settings?
5-Amino-1MQ is best reconstituted in organic solvents such as dimethyl sulfoxide (DMSO) or dimethylformamide (DMF). It exhibits low solubility in purely aqueous buffers without a co-solvent.
How does 5-amino-1MQ elevate NAD+ levels in cellular assays?
By inhibiting NNMT, 5-amino-1MQ prevents the irreversible conversion of nicotinamide (NAM) into 1-methylnicotinamide (MNA), redirecting NAM into the salvage pathway to synthesize NAD+.
What analytical methods verify the purity of PX1 Research 5-amino-1MQ?
PX1 Research verifies compound purity using Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Mass Spectrometry (MS) conducted by independent ISO 17025 accredited laboratories.
How should reconstituted 5-amino-1MQ stock solutions be stored in the lab?
Reconstituted stock solutions in DMSO should be aliquoted, sealed under dry inert gas, and stored at -20°C or -80°C to prevent degradation and moisture accumulation.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.